Taysha gene therapies announces pricing of public offering of common stock and pre-funded warrants

Dallas, may 28, 2025 (globe newswire) -- taysha gene therapies, inc. (nasdaq: tsha) (taysha or the company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (aav)-based gene therapies for severe monogenic diseases of the central nervous system (cns), today announced the pricing of an underwritten public offering of 46,868,687 shares of its common stock at a price to the public of $2.75 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 25,858,586 shares of its common stock at an offering price of $2.749 per pre-funded warrant, in each case before underwriting discounts and commissions. all of the securities are being offered by taysha. in addition, taysha has granted the underwriters a 30-day option to purchase up to an additional 10,909,090 shares of common stock at the public offering price, less underwriting discounts and commissions. the gross proceeds from the offering to taysha are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions and other offering expenses, excluding any exercise of the underwriters' option to purchase additional shares. the offering is expected to close on or about may 30, 2025, subject to customary closing conditions.
TSHA Ratings Summary
TSHA Quant Ranking